A recent study finds no association between children’s exposure to SSRIs, a common type of antidepressant, in the womb and later childhood depression.
It’s one of the first studies to look at the association between SSRIs (selective serotonin reuptake inhibitors) and brain development in young children. SSRIs are a class of medications often prescribed to treat depression, but are also used as treatment for other illnesses, such as obsessive-compulsive disorder and anxiety.
The study is in press at the journal Biological Psychiatry Global Open Science.
For the investigation, author Allison Moreau, a PhD student in the Behavioral Research and Imaging Neurogenetics (BRAIN) Lab at Washington University in St. Louis, analyzed a sample of more than 10,000 9- and 10-year-old children from the largest long-term study of brain development in the United States, the Adolescent Brain Cognitive Development (ABCD) Study.
Initially, Moreau and colleagues observed a small increase in depression among children prenatally exposed to SSRIs that was independent of family history of depression and child polygenic risk for depression. However, they found that this association was no longer significant once they subtracted from their analysis the known effect of maternal depression on a child.
“We found prenatal SSRI exposure is not associated with increased depression, after accounting for the mother’s current depression,” says Moreau.
In addition to behavioral outcomes, the researchers also looked at the children’s brain structures to determine if there might be any associations between prenatal SSRI exposure and any changes in the children’s developing brains. There, the data did reveal a difference between children who were and were not exposed in the womb to SSRIs, but it was not related to children’s depression.
Children who were exposed had a slightly thicker left lateral occipital cortex and a slightly larger surface area of the left superior parietal cortex than children who weren’t.
“Notably, the observed brain differences were small, and they were also unrelated to depression,” Moreau says. “It’s unclear if these small differences have any meaningful consequence.”
In the meantime, Moreau says the findings can be used to facilitate a conversation when it comes to clinical care and pregnancy. About 5.5% of pregnant people take SSRIs; 11% do so during their reproductive years.
“Overall, these data suggest that SSRI use during pregnancy is not independently associated with elevated depression during middle childhood (~10 years of age),” Moreau says. “The data suggest that maternal depression, not the use of SSRIs, is more related to childhood depression. That’s an important factor to keep in mind in discussions of pregnancy and mental health.”
However, this study does not resolve this question. The researchers will have the opportunity to look at these children as they grow older as the ABCD study will follow them into young adulthood. The ability to be able to return to these children and capture more data is particularly important as the average age of depression onset is 19.
“Many may feel between a rock and hard place when facing medical decisions, especially during pregnancy—these data suggest that risk for depression during middle childhood associated with prenatal SSRI exposure should not discourage SSRI use,” says Ryan Bogdan, associate professor of psychological and brain sciences, who runs the BRAIN lab.
However, he says, “Science is always evolving and more data are needed—our study evaluated depression in children from about 9- to 10-years-old. It is really important to address this question in this dataset as children continue to develop and enter peak periods of vulnerability. It is possible that we observed no independent risk because the peak window of depression vulnerability has not yet occurred.”
Support for the work came from the National Institutes of Health.
